Replimune Group Q4 2026 Earnings Report

Replimune Group EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.73
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Replimune Group Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.95 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Replimune Group Announcement Details

• Quarter: Q4 2026
• Date: 5/28/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Replimune Group (NASDAQ:REPL) is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation. The company’s pipeline also includes RP2, RP3 and RP4, each engineered with distinct cytokine or co‐stimulatory transgenes to address different tumor types and immune environments. Clinical studies to date have evaluated these candidates as monotherapies and in combination with checkpoint inhibitors, with initial data reported in melanoma, cutaneous squamous cell carcinoma and other solid tumors.

Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune designs and executes clinical trials across North America and Europe. The company’s research and manufacturing infrastructure supports rapid development and scalable production of its viral immunotherapies. Replimune maintains collaborations with academic institutions and clinical research organizations to advance its programs through late-stage studies.

Replimune is led by an experienced management team and board of directors with deep expertise in oncology drug development, virology and regulatory affairs. The company’s leadership draws on years of precedent in advancing innovative cancer treatments from early discovery into pivotal clinical trials.